Application of High-dose Insulin Therapy to Improve Liver Function and Regeneration
Recruiting now NCT06126419
Run by McGill University Health Centre/Research Institute of the McGill University Health Centre · for 18 and older · All sexes
What this study is about
The primary objective of this interventional study is determine if the future liver remnant can be optimized by improving liver function pre-operatively in patients who are scheduled for major hepatectomy. The main questions it aims to answer are: 1. Does high-dose insulin therapy improve liver function in the pre-operative setting? 2. What is the effect of high-dose insulin therapy on liver function and liver regeneration after a liver venous deprivation (LVD) procedure? 3. What is the relationship between volume hypertrophy and function in the regenerating liver? Participants will receive a 6-hour infusion of insulin and dextrose to maintain a hyperinsulinemic-normoglycemic state in the weeks prior to planned liver surgery to assess its effect on liver function measured by 99m-Tc-Mebrofenin hepatobiliary scintigraphy.
Who can join (things the study team will check)
✅ You may be able to join if…
- Age > 18 years old
- Candidate for major liver resection
- Resectable colorectal liver metastasis
🚫 You may not be able to join if…
- Inability to give consent
- Type 1 diabetes mellitus
- Uncontrolled blood glucose levels (fasting level > 10 mmol/L)
- Unresectable colorectal liver metastasis
- Extrahepatic metastatic disease that is unresectable
Where this trial is running
- McGill Univeristy Health Centre, Montreal, Quebec, Canada
Who to contact
Jennifer Kalil, MD · 514-934-1934 · jennifer.kalil@mail.mcgill.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06126419.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.